GlassScriptPhysician profile
Daniel T Zoeteman
NPI 1104969310
$10,339.36
in general payments reported to CMS, 2019-2025
40 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,318 · 2020: $1,089 · 2021: $1,775 · 2022: $1,486 · 2023: $1,423 · 2024: $2,133 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,671.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,676.20 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,449.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,141.01 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Antares Pharma, INC. | $1,083.88 | 2020-2024 | Xyosted, Tlando, Nocdurna |
| Abbvie INC. | $640.27 | 2021-2024 | Ubrelvy, Viberzi, Linzess |
| Sanofi-Aventis U.S. LLC | $481.50 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.27 | 2020-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $297.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Tolmar, INC. | $239.01 | 2023-2025 | Jatenzo |
| Verity Pharmaceuticals INC. | $191.75 | 2024-2025 | Tlando |
| Dexcom, INC. | $155.71 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $135.77 | 2019-2023 | Assurity |
| Almatica Pharma LLC | $107.02 | 2022-2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Acerus Pharmaceuticals Corporation | $97.57 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $91.01 | 2019-2025 | Zoryve |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Zoeteman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.